STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-168)	PRALUZATAMAB
PRONUNCIATION	pral” ue zat’ a mab
THERAPEUTIC CLAIM	Treatment of cancer

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human activated leukocyte cell adhesion molecule) (human monoclonal CX-191 γ1-chain), disulfide with prodomain protein (synthetic masking moiety and cleavable moiety protease substrate-containing) fusion protein with human monoclonal CX-191 κ-chain, dimer (Source: CAS)

2. Immunoglobulin G1-kappa, anti-(*Homo sapiens* CD166 antigen (Activated leukocyte cell adhesion molecule)); humanized monoclonal antibody; γ1 heavy chain humanized (1-450) [VH (*Homo sapiens* IGHV2-5*01 (89%) –(IGHD)-IGHJ4*01 (93%)) [10.7.13] (1-121) -*Homo sapiens* IGHG1*03 {CH1[R^{97}>K(217)], CH3[K^{107}>del(451)]} (122-450)], (224-270')-disulfide with κ light chain humanized (1'-270') {*N*-terminal region [synthetic masking moiety-(1'-22')- triglycyldiseryldiglycylseryl linker-(23'-30')- cleavable moiety protease substrate-containing -(31'-48')- diglycylseryl linker (49'-51')]}-(1'-51')-[humanized V-KAPPA (*Mus musculus* IGKV2-109*01 (91%) –IGKJ2*03 (92%):*Homo sapiens* IGKV2-28*01 (89%) –IGKJ2*01)-[11.3.9] (52'-163') -*Homo sapiens* IGKC*01 (164'-270')], dimer (230-230'':233-233'')-bisdisulfide (Source: USAN Program chemical consultant)

STRUCTURAL FORMULA

Heavy chain X & X''

QITLKESGPT	LVKPTQTLTL	TCTFSGFSLS	TYGMGVGWIR	QPPGKALEWL	50
ANIWWSEDKH	YSPSLKSRLT	ITKDTSKNQV	VLTITNVDPV	DTATYYCVQI	100
DYGNDYAFTY	WGQGTLVTVS	SASTKGPSVF	PLAPSSKSTS	GGTAALGCLV	150
KDYFPEPVTV	SWNSGALTSG	VHTFPAVLQS	SGLYSLSSVV	TVPSSSLGTQ	200
TYICNVNHKP	SNTKVDKKVE	PKSCDKTHTC	PPCPAPELLG	GPSVFLFPPK	250
PKDTLMISRT	PEVTCVVVDV	SHEDPEVKFN	WYVDGVEVHN	AKTKPREEQY	300
NSTYRVVSVL	TVLHQDWLNG	KEYKCKVSNK	ALPAPIEKTI	SKAKGQPREP	350
QVYTLPPSRE	EMTKNQVSLT	CLVKGFYPSD	IAVEWESNGQ	PENNYKTTPP	400
VLDSDGSFFL	YSKLTVDKSR	WQQGNVFSCS	VMHEALHNHY	TQKSLSLSPG	450

Light chain X' & X'''

QGQSGQGLCH	PAVLSAWESC	SSGGGSSGGS	AVGLLAPPGG	LSGRSDNHGG	50'
SDIVMTQSPL	SLPVTPGEPA	SISCRSSKSL	LHSNGITYLY	WYLQKPGQSP	100'
QLLIYQMSNL	ASGVPDRFSG	SGSGTDFTLK	ISRVEAEDVG	VYYCAQNLEL	150'
PYTFGQGTKL	EIKRTVAAPS	VFIFPPSDEQ	LKSGTASVVC	LLNNFYPREA	200'
KVQWKVDNAL	QSGNSQESVT	EQDSKDSTYS	LSSTLTLSKA	DYEKHKVYAC	250'
EVTHQGLSSP	VTKSFNRGEC				270'

Disulfide bridges

9'-20'	9'''-20'''	22-97	22''-97''	74'-144'	74'''-144'''
148-204	148''-204''	190'-250'	190'''-250'''	224-270'	224''-270'''
230-230''	233-233''	265-325	265''-328''	371-429	371''-429''

Glycosylation sites (N)

Asn-301 Asn-301''

MOLECULAR FORMULA	$C_{6942}H_{10740}N_{1828}O_{2176}S_{48}$ (non glycosylated)
MOLECULAR WEIGHT	156.16 kDa
TRADEMARK	None as yet
SPONSOR	CytomX Therapeutics Inc.
CODE DESIGNATIONS	CX-191
CAS REGISTRY NUMBER	2145109-70-0
UNII	X7F47LV4T7
WHO NUMBER	10940

gbk